[
  {
    "ts": "2025-08-07T13:08:00+00:00",
    "headline": "Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types",
    "summary": "Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research collaboration will investigate the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test, as an aid in postoperative therapy decisions for two cancer types: cut",
    "url": "https://finance.yahoo.com/news/mass-general-brigham-launches-two-130800514.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "05950e75-86c7-31a1-b2d1-b3a90abeeca5",
      "content": {
        "id": "05950e75-86c7-31a1-b2d1-b3a90abeeca5",
        "contentType": "STORY",
        "title": "Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types",
        "description": "",
        "summary": "Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research collaboration will investigate the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test, as an aid in postoperative therapy decisions for two cancer types: cut",
        "pubDate": "2025-08-07T13:08:00Z",
        "displayTime": "2025-08-07T13:08:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b",
          "originalWidth": 400,
          "originalHeight": 190,
          "caption": "Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FuRCtrLWo1T4qYYDhuscJw--~B/aD0xOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b.cf.webp",
              "width": 400,
              "height": 190,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L_XnLitlJHZ7Gn01q1kijg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mass-general-brigham-launches-two-130800514.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mass-general-brigham-launches-two-130800514.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DGX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]